- Conditions
- Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa
- Interventions
- EB-101
- Biological
- Lead sponsor
- Abeona Therapeutics, Inc
- Industry
- Eligibility
- 6 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 2
- States / cities
- Redwood City, California • Worcester, Massachusetts
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 255
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Osteogenesis Imperfecta
- Interventions
- Fresolimumab
- Drug
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 2
- States / cities
- Portland, Oregon • Houston, Texas
- Conditions
- Chronic Pain, Musculoskeletal Pain, Musculoskeletal Pain Disorder
- Interventions
- Empowered Relief, Move to Health, Usual Care as determined by primary care provider
- Behavioral · Other
- Lead sponsor
- Brooke Army Medical Center
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 608 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 5
- States / cities
- Fairbanks, Alaska • Schofield Barracks, Hawaii • San Antonio, Texas + 1 more
- Conditions
- Keloid, Keloid of Ear Lobe, Healthy Adults
- Interventions
- Biopsy and/or triamcinolone injection, Excisional Biopsy
- Procedure
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2023
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Epidermolysis Bullosa Dystrophica, Epidermolysis Bullosa Dystrophica, Recessive, Epidermolysis Bullosa Dystrophica Dominans
- Interventions
- Not listed
- Lead sponsor
- Krystal Biotech, Inc.
- Industry
- Eligibility
- 6 Months and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Epidermolysis Bullosa
- Interventions
- Palifermin, Fludarabine, Busulfan, Lorazepam, Alemtuzumab, Tacrolimus
- Drug
- Lead sponsor
- Columbia University
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2015
- U.S. locations
- 3
- States / cities
- Aurora, Colorado • Chicago, Illinois • New York, New York
- Conditions
- Recessive Dystrophic Epidermolysis Bullosa
- Interventions
- Prademagene Zamikeracel
- Combination Product
- Lead sponsor
- Abeona Therapeutics, Inc
- Industry
- Eligibility
- Not listed
- Enrollment
- 250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2045
- U.S. locations
- 4
- States / cities
- Palo Alto, California • Aurora, Colorado • Chicago, Illinois + 1 more
- Conditions
- Acne Keloidalis Nuchae
- Interventions
- Targeted UV-B
- Radiation
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Osteogenesis Imperfecta
- Interventions
- Vitamin D, Calcium
- Dietary Supplement
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 5 Years to 19 Years
- Enrollment
- 71 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Dystrophic Epidermolysis Bullosa, DEB - Dystrophic Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa, Dominant Dystrophic Epidermolysis Bullosa
- Interventions
- Open Label Topical Beremagene Geperpavec (B-VEC)
- Biological
- Lead sponsor
- Krystal Biotech, Inc.
- Industry
- Eligibility
- 2 Months and older
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 6
- States / cities
- Rancho Santa Margarita, California • Redwood City, California • Coral Gables, Florida + 3 more
- Conditions
- Chronic Pain Syndrome, Chronic Daily Headache, Functional Abdominal Pain Syndrome, Musculoskeletal Pain Disorder, CRPS (Complex Regional Pain Syndromes)
- Interventions
- Offset analgesia
- Other
- Lead sponsor
- Boston Children's Hospital
- Other
- Eligibility
- 10 Years to 17 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Waltham, Massachusetts
- Conditions
- Osteogenesis Imperfecta
- Interventions
- Humatrope
- Drug
- Lead sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- NIH
- Eligibility
- 3 Years to 16 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1991 – 2017
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Alport Syndrome
- Interventions
- Not listed
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 5 Years to 65 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Osteoarthritis, Rheumatoid Arthritis, Traumatic Arthritis, Polyarthritis, Collagen Disorders and/or Avascular Necrosis of the Femoral Condyle, Post-traumatic Loss of Joint Configuration, Moderate Valgus, Varus, or Flexion Deformities
- Interventions
- NexGen TM Monoblock Tibia, NexGen TM Modular Tibia
- Device
- Lead sponsor
- Zimmer Biomet
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 7
- States / cities
- Torrance, California • Wheat Ridge, Colorado • Mooresville, Indiana + 4 more
- Conditions
- Osteogenesis Imperfecta
- Interventions
- Risedronate Oral Tablet
- Drug
- Lead sponsor
- Hospital for Special Surgery, New York
- Other
- Eligibility
- 6 Years to 100 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2027
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Hypertrophic Scar, Keloid Scar
- Interventions
- RD047-023, Predicate Device
- Device
- Lead sponsor
- Oculus Innovative Sciences, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2012
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Rheumatologic Disease, Autoimmune Diseases
- Interventions
- Video comprised of AIRD patient narratives on COVID-19 vaccination thoughts and experiences, Video on the importance of good oral health for patients with AIRD, Brochure on COVID-19 vaccination in AIRD patients, Patient Navigation, Brochure on the importance of good oral health in AIRD patients
- Behavioral
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,170 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 4
- States / cities
- Birmingham, Alabama • Evanston, Illinois • Boston, Massachusetts + 1 more
- Conditions
- Osteogenesis Imperfecta
- Interventions
- AGA2115, Placebo
- Drug
- Lead sponsor
- Angitia Incorporated Limited
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Lake Forest, California
- Conditions
- Osteogenesis Imperfecta
- Interventions
- Not listed
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 10 Years to 100 Years
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2027
- U.S. locations
- 2
- States / cities
- Los Angeles, California • Houston, Texas
- Conditions
- Keloid Scar
- Interventions
- Scripted lecture ("educational information talk")
- Behavioral
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Keloid
- Interventions
- History of prior Surgery, History of Radiation Therapy
- Procedure · Radiation
- Lead sponsor
- Tirgan, Michael H., M.D.
- Individual
- Eligibility
- Not listed
- Enrollment
- 5,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2023
- U.S. locations
- 2
- States / cities
- New York, New York • San Antonio, Texas
- Conditions
- Hypermobile Ehlers-Danlos Syndrome, Hypermobile Spectrum Disorder, Ehlers-Danlos Syndrome
- Interventions
- Transcutaneous Auricular Neurostimulation
- Device
- Lead sponsor
- Medical University of South Carolina
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Charleston, South Carolina
- Conditions
- Diet Habit, Rheumatologic Disease, Autoimmune Diseases, Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Dermatomyositis/polymyositis, Sjogren's Syndrome, Systemic Lupus Erythematous, Scleroderma, Fibromyalgia
- Interventions
- Not listed
- Lead sponsor
- University of Central Florida
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Orlando, Florida
- Conditions
- Fibrosis, Skin Scarring, Skin Wound, Hypertrophic Scar, Scar, Keloid
- Interventions
- LED-RL phototherapy, Mock irradiation
- Device
- Lead sponsor
- State University of New York - Downstate Medical Center
- Other
- Eligibility
- Not listed
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Brooklyn, New York